178 related articles for article (PubMed ID: 35417530)
21. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression.
Yao ZG; Li WH; Hua F; Cheng HX; Zhao MQ; Sun XC; Qin YJ; Li JM
J Neuropathol Exp Neurol; 2017 Dec; 76(12):1000-1007. PubMed ID: 29136455
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
McGuire JJ; Nerlakanti N; Lo CH; Tauro M; Utset-Ward TJ; Reed DR; Lynch CC
Int J Cancer; 2020 Nov; 147(10):2811-2823. PubMed ID: 32599665
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial Caseinolytic Protease P: A Possible Novel Prognostic Marker and Therapeutic Target in Cancer.
Cormio A; Sanguedolce F; Pesce V; Musicco C
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207660
[TBL] [Abstract][Full Text] [Related]
26. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.
Booth L; Roberts JL; Conley A; Cruickshanks N; Ridder T; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 Mar; 15(3):305-16. PubMed ID: 24351423
[TBL] [Abstract][Full Text] [Related]
27. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
28. Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma.
Das A; Henderson F; Lowe S; Wallace GC; Vandergrift WA; Lindhorst SM; Varma AK; Infinger LK; Giglio P; Banik NL; Patel SJ; Cachia D
Cancer Chemother Pharmacol; 2018 Dec; 82(6):945-952. PubMed ID: 30209569
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Marampon F; Leoni F; Mancini A; Pietrantoni I; Codenotti S; Ferella L; Megiorni F; Porro G; Galbiati E; Pozzi P; Mascagni P; Budillon A; Maggio R; Tombolini V; Fanzani A; Gravina GL; Festuccia C
J Cancer Res Clin Oncol; 2019 Feb; 145(2):393-409. PubMed ID: 30474756
[TBL] [Abstract][Full Text] [Related]
32. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
[TBL] [Abstract][Full Text] [Related]
33. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.
Ferrarini I; Louie A; Zhou L; El-Deiry WS
Mol Cancer Ther; 2021 Sep; 20(9):1572-1583. PubMed ID: 34224362
[TBL] [Abstract][Full Text] [Related]
34. miR-3189-targeted GLUT3 repression by HDAC2 knockdown inhibits glioblastoma tumorigenesis through regulating glucose metabolism and proliferation.
Kwak S; Park SH; Kim SH; Sung GJ; Song JH; Jeong JH; Kim H; Ha CH; Kim SW; Choi KC
J Exp Clin Cancer Res; 2022 Mar; 41(1):87. PubMed ID: 35260183
[TBL] [Abstract][Full Text] [Related]
35. Dual-targeting of aberrant glucose metabolism in glioblastoma.
Shen H; Decollogne S; Dilda PJ; Hau E; Chung SA; Luk PP; Hogg PJ; McDonald KL
J Exp Clin Cancer Res; 2015 Feb; 34(1):14. PubMed ID: 25652202
[TBL] [Abstract][Full Text] [Related]
36. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
37. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
[TBL] [Abstract][Full Text] [Related]
38. Quisinostat is a brain-penetrant radiosensitizer in glioblastoma.
Lo Cascio C; Margaryan T; Luna-Melendez E; McNamara JB; White CI; Knight W; Ganta S; Opachich Z; Cantoni C; Yoo W; Sanai N; Tovmasyan A; Mehta S
JCI Insight; 2023 Nov; 8(22):. PubMed ID: 37991020
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
40. Potent ClpP agonists with anticancer properties bind with improved structural complementarity and alter the mitochondrial N-terminome.
Mabanglo MF; Wong KS; Barghash MM; Leung E; Chuang SHW; Ardalan A; Majaesic EM; Wong CJ; Zhang S; Lang H; Karanewsky DS; Iwanowicz AA; Graves LM; Iwanowicz EJ; Gingras AC; Houry WA
Structure; 2023 Feb; 31(2):185-200.e10. PubMed ID: 36586405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
